Literature DB >> 33913091

Dosimetric impact of rectum and bladder anatomy and intrafractional prostate motion on hypofractionated prostate radiation therapy.

M Roch1, A Zapatero2, P Castro3, D Hernández3, M Chevalier4, F García-Vicente5.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the dosimetric impact on hypofractionated prostate radiation therapy of two geometric uncertainty sources: rectum and bladder filling and intrafractional prostate motion.
MATERIALS AND METHODS: This prospective study included 544 images (375 pre-treatment cone-beam CT [CBCT] and 169 post-treatment CBCT) from 15 prostate adenocarcinoma patients. We recalculated the dose on each pre-treatment CBCT once the positioning errors were corrected. We also recalculated two dose distributions on each post-treatment CBCT, either using or not intrafractional motion correction. A correlation analysis was performed between CBCT-based dose and rectum and bladder filling as well as intrafraction prostate displacements.
RESULTS: No significant differences were found between administered and planned rectal doses. However, we observed an increase in bladder dose due to a lower bladder filling in 66% of treatment fractions. These differences were reduced at the end of the fraction since the lower bladder volume was compensated by the filling during the treatment session. A statistically significant reduction in target volume coverage was observed in 27% of treatment sessions and was correlated with intrafractional prostate motion in sagittal plane > 4 mm.
CONCLUSIONS: A better control of bladder filling is recommended to minimize the number of fractions in which the bladder volume is lower than planned. Fiducial mark tracking with a displacement threshold of 5 mm in any direction is recommended to ensure that the prescribed dose criteria are met.
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Dosimetric impact; Hypofractionation; Intrafractional motion; Prostate cancer; Rectum/bladder filling

Mesh:

Year:  2021        PMID: 33913091     DOI: 10.1007/s12094-021-02628-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  6 in total

1.  Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation.

Authors:  Barbara Alicja Jereczek-Fossa; Alessia Surgo; Patrick Maisonneuve; Andrea Maucieri; Marianna Alessandra Gerardi; Dario Zerini; Giulia Marvaso; Delia Ciardo; Stefania Volpe; Damaris Patricia Rojas; Giulia Riva; Ombretta Alessandro; Samantha Dicuonzo; Giuseppe Fanetti; Paola Romanelli; Anna Starzyńska; Federica Cattani; Raffaella Cambria; Cristiana Fodor; Cristina Garibaldi; Chiara Romanò; Ottavio De Cobelli; Roberto Orecchia
Journal:  Radiol Med       Date:  2018-09-15       Impact factor: 3.469

2.  Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.

Authors:  Michel Ghilezan; Di Yan; Jian Liang; David Jaffray; John Wong; Alvaro Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-12-01       Impact factor: 7.038

3.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

4.  Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.

Authors:  Maria Thor; Joseph O Deasy; Rebecca Paulus; W Robert Lee; Mahul B Amin; Deborah W Bruner; Daniel A Low; Amit B Shah; Shawn C Malone; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; Elizabeth M Gore; Michele Albert; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Gregory P Swanson; Stephanie L Pugh; Howard M Sandler
Journal:  Radiother Oncol       Date:  2019-03-05       Impact factor: 6.280

5.  Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.

Authors:  David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

6.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

Authors:  Michael J Zelefsky; Marisa Kollmeier; Brett Cox; Anthony Fidaleo; Dahlia Sperling; Xin Pei; Brett Carver; Jonathan Coleman; Michael Lovelock; Margie Hunt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.